Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.1312 | 0.3065 | 0.5 |
Chlamydia trachomatis | oxoacyl-ACP synthase III | 0.1312 | 0.3065 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.1312 | 0.3065 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.017 | 0 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1312 | 0.3065 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.017 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.017 | 0 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.3893 | 1 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.1312 | 0.3065 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1312 | 0.3065 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.017 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.017 | 0 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.1312 | 0.3065 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.1312 | 0.3065 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 33 % | In vitro Dopamine receptor D2 affinity by using [3H]-Spiperone as the radioligand in rat limbic system at 1 microM concentration of compound | ChEMBL. | 2888898 |
Ki (binding) | nM | In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]-Spiperone displacement; No data. | ChEMBL. | 2888898 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.